<DOC>
	<DOCNO>NCT00637520</DOCNO>
	<brief_summary>We hypothesize insulin resistance characteristic nonalcoholic fatty liver disease compare age , gender , non-diabetic BMI-matched control subject , healthy non-cirrhotic , non-steatotic liver disease .</brief_summary>
	<brief_title>Insulin Resistance Nonalcoholic Fatty Liver Disease : A Case Control Study</brief_title>
	<detailed_description>Purpose study : To date , case control study evaluate insulin resistance ( IR ) nonalcoholic fatty liver disease ( NALFD ) publish . We hypothesize IR characteristic NAFLD compare age , gender , non-diabetic BMI-matched control subject , healthy non-cirrhotic , non-steatotic liver disease . The following aim test central hypothesis : Specific Aim 1 : Measure IR insulin clearance use intravenous glucose tolerance test Bergman 's Minimal Modeling patient NAFLD compare match control ( healthy non-steatotic hepatitis ) . This aim test postulate IR necessary development hepatic steatosis compare healthy ( non-steatotic liver ) . It also test postulate IR present confound factor ( impaired hepatic clearance ) NAFLD compare non-steatotic form hepatitis . Specific Aim 2 : Determine IR associate altered parameter lipid metabolism compare matched control . This aim address whether IR ( present ) associate abnormal lipid parameter NAFLD observe irrespective presence hepatic steatosis . Specific Aim 3 : Measure differential effect IR lipid metabolism peripheral mononuclear cell ( PBMC ) inflammatory response associate hepatocyte mitochondrial ultrastructure measure oxidative stress . Since increase oxidative stress bioenergetic failure associate hepatic steatosis , aim address whether IR and/or steatosis result impair inflammatory response increase oxidative stress compare control . Changes innate immune response determine measure inflammatory index think correlate obesity , IR , and/or chronic hepatitis : 1 ) interleukin ( IL-2 , IL-4 , IL-6 , IL-10 , IL-12 , IL-18 ) 2 ) C-reactive protein , 3 ) TNF-a TGF-B 4 ) IFN-A &amp; IFN-g , 5 ) adiponectin . Changes oxidative stress determine measure key index oxidative stress damage . These include , ) reduce oxidize glutathione ( GSH GSSG ) ; oxidation/reduction status ) , b ) malondialdehyde ( MDA ; lipid peroxidation ) , c ) nitrotyrosine ( NO damage ) , ) 8OHdG 8OHG ( DNA damage ) . Background significance : Obesity , diabetes , hypertriglyceridemia , hypertension , coronary heart disease constitute phenotype common individual either IR syndrome NAFLD1-12 . Furthermore , hepatic steatosis , fibrosis , cirrhosis characteristic NAFLD also frequent histologic finding patient IR 3-7 . Together , data beg question whether NAFLD IR causally associate . Support notion derive recent observation IR may strong , independent predictor NAFLD , even absence glucose intolerance 13 . Moreover , since NAFLD report occur lean subject ( BMI great 25 ) normoglycemia 14 , 15 , reasonable postulate NAFLD may early manifestation consequence IR . Increased oxidative stress important pathogenic mechanism obesity-associated metabolic syndrome 16 . Fat accumulation correlate systemic oxidative stress human mouse . However , increase oxidative stress instigator metabolic syndrome patient NAFLD compare control yet investigate . Furthermore , impaired cytokine medicate inflammatory response show correlate body mass index across broad range obesity may mediate hepatic steatosis and/or lead mitochondrial dysfunction hepatocytes 17 , 18 . Discerning whether NAFLD attributable increase oxidative stress and/or abnormality innate immune response would imperative identify potentially useful therapeutic target obesity-associated liver disease .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Biochemical liver histologic feature confirm presence healthy liver , fatty liver , and/or nonfatty liver inflammation due another etiology besides NAFLD . &gt; 20 gram alcohol/day Impaired oral glucose tolerance test Clinical histologic evidence cirrhosis ( stage 56 fibrosis ) portal hypertension . Chronic hepatitis C infection Known diabetes mellitus need insulinsensitizing agent and/or insulin therapy . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Nonalcoholic Fatty Liver Disease</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Lipid Metabolism</keyword>
</DOC>